Sylvia van Dyk1, Kailash Narayan2, David Bernshaw3, Srinivas Kondalsamy-Chennakesavan4, Pearly Khaw3, Ming Yin Lin3, Michal Schneider5. 1. Radiation Therapy Services, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Electronic address: sylvia.vandyk@petermac.org. 2. Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Department of Obstetrics and Gynaecology, Melbourne University, Melbourne, Victoria, Australia. 3. Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. 4. Rural Clinical School, University of Queensland, Toowoomba, Queensland, Australia. 5. Department of Medical Imaging and Radiation Science, Monash University, Clayton, Victoria, Australia.
Abstract
PURPOSE: The aim of this study was to report clinical outcomes in a series of patients who underwent serial ultrasound and a single MRI to plan and verify intracavitary brachytherapy. METHODS AND MATERIALS: Data for patients who were referred for curative intent radiotherapy for International Federation of Gynecology and Obstetrics (FIGO) Stage 1-1V cervix cancer between January 2007 and March 2012 were analyzed. All patients received external beam radiotherapy with concurrent chemotherapy and sequential high-dose rate brachytherapy. Brachytherapy was planned and verified using serial ultrasound imaging and a single MRI. RESULTS: Data from 191 patients were available for analyses. The median (range) followup time was 5.08 (0.25-8.25) years. Five-year local control, failure-free survival, cancer-specific survival, and overall survival were 86%, 57.3%, 70% and 63%, respectively. Mean (standard deviation) combined external beam radiotherapy and brachytherapy target doses, equivalent to doses in 2 Gy fractions were 80.4 Gy10 (3.89), median (range) 80 (49-96) Gy10. Grade 3 or greater gastrointestinal, genitourinary, or vaginal late toxicity occurred in 3%, 1.6%, and 2% of patients, respectively. Survival, patterns of failure, and late complication rates were similar to published series of MRI/CT-based brachytherapy practices. CONCLUSIONS: This large study demonstrates that favorable treatment outcomes can be obtained using a pragmatic and innovative combination of ultrasound and MR imaging. Crown Copyright Â
PURPOSE: The aim of this study was to report clinical outcomes in a series of patients who underwent serial ultrasound and a single MRI to plan and verify intracavitary brachytherapy. METHODS AND MATERIALS: Data for patients who were referred for curative intent radiotherapy for International Federation of Gynecology and Obstetrics (FIGO) Stage 1-1V cervix cancer between January 2007 and March 2012 were analyzed. All patients received external beam radiotherapy with concurrent chemotherapy and sequential high-dose rate brachytherapy. Brachytherapy was planned and verified using serial ultrasound imaging and a single MRI. RESULTS: Data from 191 patients were available for analyses. The median (range) followup time was 5.08 (0.25-8.25) years. Five-year local control, failure-free survival, cancer-specific survival, and overall survival were 86%, 57.3%, 70% and 63%, respectively. Mean (standard deviation) combined external beam radiotherapy and brachytherapy target doses, equivalent to doses in 2 Gy fractions were 80.4 Gy10 (3.89), median (range) 80 (49-96) Gy10. Grade 3 or greater gastrointestinal, genitourinary, or vaginal late toxicity occurred in 3%, 1.6%, and 2% of patients, respectively. Survival, patterns of failure, and late complication rates were similar to published series of MRI/CT-based brachytherapy practices. CONCLUSIONS: This large study demonstrates that favorable treatment outcomes can be obtained using a pragmatic and innovative combination of ultrasound and MR imaging. Crown Copyright Â
Authors: José Richart; Vicente Carmona-Meseguer; Teresa García-Martínez; Antonio Herreros; Antonio Otal; Santiago Pellejero; Ana Tornero-López; José Pérez-Calatayud Journal: Rep Pract Oncol Radiother Date: 2018-07-23
Authors: Mario Federico; Carmen Rosa Hernandez-Socorro; Ivone Ribeiro; Jesus Gonzalez Martin; Maria Dolores Rey-Baltar Oramas; Marta Lloret Saez-Bravo; Pedro Carlos Lara Jimenez Journal: Radiat Oncol Date: 2019-10-04 Impact factor: 3.481